ANXA1: A New Target for Treating Acute Myeloid Leukemia
Author Information
Author(s): Shao Gang, Wang Xi, Zheng Yiting, Ma Junjie, Wang Lei, Yan Zhibin, Sun Zeyu, Zhang Shuyuan, Wu Hongzhang, Lv Yudie, Huang Hemiao, Li Jianhu, Zhu Tianyi, Yang Bing, Wang Nanxi, Chen Tao, Guo Xuancheng, Jin Yuanting, Kang Jian, Wang Huafeng, Cao Yihai, Fu Caiyun
Primary Institution: Zhejiang Sci‐Tech University
Hypothesis
Is ANXA1 a negative regulator of Notch1 function in acute myeloid leukemia (AML)?
Conclusion
Targeting ANXA1 could provide an effective approach for treating AML by restoring Notch1 function.
Supporting Evidence
- High ANXA1 expression correlates with increased proliferation of AML cells.
- ANXA1 directly interacts with Notch1, leading to its degradation.
- Knockdown of ANXA1 reduces AML cell proliferation.
- Clinical samples show a negative correlation between ANXA1 and Notch1/p15 expression.
- Targeting ANXA1 with peptides inhibits AML cell growth in vitro and in vivo.
Takeaway
Researchers found that a protein called ANXA1 helps cancer cells grow by stopping another protein, Notch1, from doing its job. If we can block ANXA1, we might be able to help treat leukemia better.
Methodology
The study used gene expression analysis, shRNA knockdown, and in vivo mouse models to investigate the role of ANXA1 in AML.
Participant Demographics
24 AML patients and 16 volunteers were included in the study.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website